Leung Sheldon, Fiorotti Corinna, Bibik Michael, Brown David, Gleeson Martin A, Gorovits Boris
At the time of writing: Pfizer, 1 Burtt Rd, Andover, MA 01810, USA; At the time of publishing: Selecta Biosciences, 480 Arsenal Way, Watertown, MA 02472, USA.
At the time of writing: Pfizer, 1 Burtt Rd, Andover, MA 01810, USA; At the time of publishing: BioAgilytix, Durham, North Carolina, USA.
Bioanalysis. 2019 Apr;11(8):703-712. doi: 10.4155/bio-2018-0072. Epub 2019 Apr 17.
Characterization of antidrug antibody (ADA)-like reactivity has emerged as critical element of bioanalytical design and assessment of compound immunogenicity risk. Multiplex immunoassay was applied to detect and characterize ADA like reactivity using Photonic Ring Immunoassay platform (Genalyte). Specific binding to human IgE or human recombinant IL21-receptor-Fc fusion using exogenous reagents as surrogates for drug-specific reactivity was investigated. Multiplexed assay format allowed identification of spiked antihuman IgE reactivity as murine IgG1 and endogenous antihuman recombinant IL21-receptor-Fc reactivity in rheumatoid arthritis sera as antihuman Fc-specific binding. The ability of a multiplex immunoassay platform to identify isotype and domain specificity of antidrug immunoglobulins was shown to be effective and should be considered when screening and characterizing pre- and post-dose ADA reactivity.